ABRAMS: You are right that we do not want to see trials that a lot of time and effort has been put into, and patients have joined, and then don’t meet their enrollment goals. We have to do more, and we’ve recognized that.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
